Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01GSE
|
|||
| Former ID |
DIB013786
|
|||
| Drug Name |
E-10030
|
|||
| Synonyms |
PDGF-B antagonist (AMD), Eyetech/Archemix; PDGF-B antagonist (AMD), (OSI) Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), Eyetech/Archemix; Platelet-derived growth factor B antagonist, (macular degernation), (OSI) Eyetech/Archemix
Click to Show/Hide
|
|||
| Indication | Macular degeneration [ICD-11: 9B78.3; ICD-10: H35.3; ICD-9: 362.5] | Phase 2 | [1] | |
| Company |
Archemix Corp
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01089517) A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration. U.S. National Institutes of Health. | |||
| REF 2 | Aptamers as therapeutics. Nat Rev Drug Discov. 2010 Jul;9(7):537-50. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.